Products for Research Use Only

WCY-8-67

CAT: 0804-HY-178500-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-178500-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
WCY-8-67 is an orally active and selective USP5 inhibitor, with an IC50 value of 1.33 μM. WCY-8-67 induces apoptosis and suppresses JAK/STAT3 and PI3K/AKT signaling pathways in vitro. WCY-8-67 inhibits proliferation of AE-positive AML cells, induces G1 phase arrest and differentiation of AML cells. WCY-8-67 demonstrates potent anti-leukemic efficacy in mice. WCY-8-67 can be used for the study of acute myeloid leukemia[1].
CAS Number
3052618-54-6
UNSPSC
12352005
Target
Akt; Apoptosis; Deubiquitinase; JAK; PI3K; STAT
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Smiles
CN(C)CCN(C1=C2C(CN(C3=C4C=CC=CC4=C(F)C=C3)C2)=NC(N5CCNCC5)=N1)C
Molecular Formula
C25H32FN7
Molecular Weight
449.57
References & Citations
[1]Ma L, et al. USP5 inhibition enables potential therapy for t (8;21) AML through ubiquitin-mediated AML1-ETO degradation in patient-derived xenografts. Sci Transl Med. 2025 Sep 24;17 (817) :eadt9100.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported